Thermogenesis Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.1601
- Today's High:
- $1.2
- Open Price:
- $1.2
- 52W Low:
- $1.03
- 52W High:
- $16.6455
- Prev. Close:
- $1.19
- Volume:
- 20130
Company Statistics
- Market Cap.:
- $2.90 million
- Book Value:
- 1.545
- Revenue TTM:
- $9.64 million
- Operating Margin TTM:
- -65.57%
- Gross Profit TTM:
- $3.49 million
- Profit Margin:
- -145.49%
- Return on Assets TTM:
- -20.28%
- Return on Equity TTM:
- -357.82%
Company Profile
Thermogenesis Holdings Inc had its IPO on 1995-08-18 under the ticker symbol THMO.
The company operates in the Healthcare sector and Medical Devices industry. Thermogenesis Holdings Inc has a staff strength of 40 employees.
Stock update
Shares of Thermogenesis Holdings Inc opened at $1.2 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.16 - $1.2, and closed at $1.18.
This is a -0.84% slip from the previous day's closing price.
A total volume of 20,130 shares were traded at the close of the day’s session.
In the last one week, shares of Thermogenesis Holdings Inc have increased by +0.85%.
Thermogenesis Holdings Inc's Key Ratios
Thermogenesis Holdings Inc has a market cap of $2.90 million, indicating a price to book ratio of 1.0004 and a price to sales ratio of 0.4593.
In the last 12-months Thermogenesis Holdings Inc’s revenue was $9.64 million with a gross profit of $3.49 million and an EBITDA of $-5267000. The EBITDA ratio measures Thermogenesis Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Thermogenesis Holdings Inc’s operating margin was -65.57% while its return on assets stood at -20.28% with a return of equity of -357.82%.
In Q2, Thermogenesis Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 25%.
Thermogenesis Holdings Inc’s PE and PEG Ratio
- Forward PE
- 2.2841
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-8.25 per share while it has a forward price to earnings multiple of 2.2841 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Thermogenesis Holdings Inc’s profitability.
Thermogenesis Holdings Inc stock is trading at a EV to sales ratio of 1.0913 and a EV to EBITDA ratio of -2.1454. Its price to sales ratio in the trailing 12-months stood at 0.4593.
Thermogenesis Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $17.61 million
- Total Liabilities
- $10.99 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $590000
- Dividend Payout Ratio
- 0%
Thermogenesis Holdings Inc ended 2024 with $17.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.61 million while shareholder equity stood at $3.83 million.
Thermogenesis Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $10.99 million in other current liabilities, 2000.00 in common stock, $-273539000.00 in retained earnings and $781000.00 in goodwill. Its cash balance stood at $4.45 million and cash and short-term investments were $4.45 million. The company’s total short-term debt was $7,161,000 while long-term debt stood at $0.
Thermogenesis Holdings Inc’s total current assets stands at $8.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $774000.00 compared to accounts payable of $508000.00 and inventory worth $2.66 million.
In 2024, Thermogenesis Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $590000.
Comparatively, Thermogenesis Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.18
- 52-Week High
- $16.6455
- 52-Week Low
- $1.03
- Analyst Target Price
- $5
Thermogenesis Holdings Inc stock is currently trading at $1.18 per share. It touched a 52-week high of $16.6455 and a 52-week low of $16.6455. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $1.29 and 200-day moving average was $2.54 The short ratio stood at 0.15 indicating a short percent outstanding of 0%.
Around 1433.3% of the company’s stock are held by insiders while 1551.3% are held by institutions.
Frequently Asked Questions About Thermogenesis Holdings Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.